Výsledky vyhledávání - "C.-L. Loprinzi"

Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigation

Autor: A, Jatoi, C L, Loprinzi, J A, Sloan, G G, Klee, H E, Windschitl

Publikováno v: Cancer. 92(3)

Anorexia is a noxious symptom, and over half of patients with advanced cancer experience it. Neuropeptide Y (NPY), leptin, and cholecystokinin 8 (CCK8) have been implicated.This exploratory study 1) compared circulating concentrations of NPY and lept

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::14e99a1b355d63930a651c236c651ea5
https://pubmed.ncbi.nlm.nih.gov/11505408

Zobrazit plný text záznamu

Current management of cancer-associated anorexia and weight loss

Autor: A, Jatoi, C L, Loprinzi

Publikováno v: Oncology (Williston Park, N.Y.). 15(4)

Loss of appetite and weight predict a poor prognosis for cancer patients. Although caloric supplementation might benefit subgroups of patients--specifically, perioperative, severely malnourished cancer patients, stem cell and bone marrow transplant p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::dbb51d15a2d7733872b758af6c0a6f2c
https://pubmed.ncbi.nlm.nih.gov/11346935

Zobrazit plný text záznamu

Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer

Autor: J N, Ingle, V J, Suman, P A, Johnson, J E, Krook, J A, Mailliard, R H, Wheeler, C L, Loprinzi, E A, Perez, V C, Jordan, M, Dowsett

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 5(7)

The goals of this clinical trial involving postmenopausal women with metastatic breast cancer were to: (a) examine the effects of letrozole on tamoxifen (TAM) pharmacokinetics; (b) examine estrogen suppression in patients receiving TAM plus letrozole

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8da16609ccbba9c209376bde47145a9e
https://pubmed.ncbi.nlm.nih.gov/10430063

Zobrazit plný text záznamu

A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma

Autor: J N, Ingle, V J, Suman, C G, Kardinal, J E, Krook, J A, Mailliard, M H, Veeder, C L, Loprinzi, R J, Dalton, L C, Hartmann, C A, Conover, M N, Pollak

Publikováno v: Cancer. 85(6)

Tamoxifen (TAM) is generally considered the hormonal agent of choice for postmenopausal women with hormone receptor positive breast carcinoma. The somatostatin analogues, including octreotide, have demonstrated inhibition of breast carcinoma cell lin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2462e9c9f00ab0c2e32975c9dcb1a696
https://pubmed.ncbi.nlm.nih.gov/10189133

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání